Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Cancer Therapies02:49

Cancer Therapies

7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Membrane-Anchored Serine Protease Inhibitors: Physiological Functions, Mechanisms, and Roles in Cancer.

International journal of molecular sciences·2026
Same author

Metabolomics-Based Liquid Biopsy for Predicting Clinically Significant Prostate Cancer.

Cancers·2025
Same author

Spint1 disruption in mouse pancreas leads to glucose intolerance and impaired insulin production involving HEPSIN/MAFA.

Nature communications·2024
Same author

Predicting Clinically Significant Prostate Cancer Using Urine Metabolomics via Liquid Chromatography Mass Spectrometry.

The world journal of men's health·2024
Same author

Mature neurons from iPSCs unveil neurodegeneration-related pathways in mucopolysaccharidosis type II: GSK-3β inhibition for therapeutic potential.

Cell death & disease·2024
Same author

An induced pluripotent stem cell-based model identifies molecular targets of vincristine neurotoxicity.

Disease models & mechanisms·2022

Related Experiment Video

Updated: May 28, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.

Yan-You Liao1, Chia-Luen Tsai2, Hsiang-Po Huang2

  • 1Department of Medicine, National Taiwan University College of Medicine, Taipei 100233, Taiwan.

Cancers
|February 13, 2025
PubMed
Summary

Third-generation EGFR TKIs improve outcomes for non-small-cell lung cancer (NSCLC) but resistance emerges. Combination therapies combining osimertinib with other treatments show promise for overcoming resistance and improving survival in EGFR-mutated NSCLC.

Keywords:
combination therapynon-small-cell lung cancerosimertinib resistance

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K

Related Experiment Videos

Last Updated: May 28, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small-cell lung cancer (NSCLC) with EGFR mutations is a major global health concern.
  • Third-generation EGFR tyrosine kinase inhibitors (TKIs) like osimertinib are effective but acquired resistance is inevitable.
  • Mechanisms of resistance include on-target mutations (e.g., C797S), pathway activation (e.g., MET amplification), and tumor microenvironment alterations.

Purpose of the Study:

  • To review the evolving landscape of combination therapies for third-generation EGFR TKIs in NSCLC.
  • To explore strategies pairing osimertinib with radiotherapy, anti-angiogenic agents, immune checkpoint inhibitors, and other targeted drugs.
  • To discuss the biological rationale, preclinical data, and clinical evidence for these combination approaches.

Main Methods:

  • Literature review of preclinical studies and clinical trials.
  • Analysis of combination strategies involving osimertinib.
  • Evaluation of resistance mechanisms and their circumvention.

Main Results:

  • Combination therapies aim to enhance or prolong the efficacy of third-generation EGFR TKIs.
  • Strategies are being developed to overcome diverse resistance mechanisms, including on-target mutations and pathway activations.
  • Combinations may improve survival and maintain a favorable safety profile in EGFR-mutated NSCLC.

Conclusions:

  • Combination therapies represent a promising strategy to address resistance to third-generation EGFR TKIs.
  • Individualized treatment approaches integrating various modalities are crucial for durable responses.
  • Further research and clinical trials are needed to optimize these combinations for improved patient outcomes and quality of life in EGFR-mutated NSCLC.